Titre : Gouvernement fédéral

Gouvernement fédéral : Questions médicales fréquentes

Termes MeSH sélectionnés :

Multicenter Studies as Topic
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Gouvernement fédéral : Questions médicales les plus fréquentes", "headline": "Gouvernement fédéral : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Gouvernement fédéral : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-03-11", "dateModified": "2025-03-06", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Gouvernement fédéral" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Agences gouvernementales", "url": "https://questionsmedicales.fr/mesh/D006077", "about": { "@type": "MedicalCondition", "name": "Agences gouvernementales", "code": { "@type": "MedicalCode", "code": "D006077", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "N03.540.400" } } }, "about": { "@type": "MedicalCondition", "name": "Gouvernement fédéral", "alternateName": "Federal Government", "code": { "@type": "MedicalCode", "code": "D035082", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Sara Allin", "url": "https://questionsmedicales.fr/author/Sara%20Allin", "affiliation": { "@type": "Organization", "name": "North American Observatory on Health Systems and Policies, Toronto, ON Canada." } }, { "@type": "Person", "name": "Gul Mehar Javaid Bukhari", "url": "https://questionsmedicales.fr/author/Gul%20Mehar%20Javaid%20Bukhari", "affiliation": { "@type": "Organization", "name": "Federal Medical & Dental College, Islamabad, Pakistan." } }, { "@type": "Person", "name": "R U Khabriev", "url": "https://questionsmedicales.fr/author/R%20U%20Khabriev", "affiliation": { "@type": "Organization", "name": "N. A. Semashko National Research Institute of Public Health, 105064, Moscow, Russia." } }, { "@type": "Person", "name": "Lizhen Cui", "url": "https://questionsmedicales.fr/author/Lizhen%20Cui", "affiliation": { "@type": "Organization", "name": "" } }, { "@type": "Person", "name": "Noël E Smith", "url": "https://questionsmedicales.fr/author/No%C3%ABl%20E%20Smith", "affiliation": { "@type": "Organization", "name": "American Academy of PAs, 2318 Mill Road, Suite 1300, Alexandria, VA 22314." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Estimation of the physiologic ability and surgical stress scoring system as a useful predictor of postoperative recurrence in patients with stage II colorectal cancer: a multicenter study.", "datePublished": "2023-02-15", "url": "https://questionsmedicales.fr/article/36790474", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s00595-023-02656-2" } }, { "@type": "ScholarlyArticle", "name": "The 31-gene expression profile test informs sentinel lymph node biopsy decisions in patients with cutaneous melanoma: results of a prospective, multicenter study.", "datePublished": "2023-01-16", "url": "https://questionsmedicales.fr/article/36617959", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1080/03007995.2023.2165813" } }, { "@type": "ScholarlyArticle", "name": "A Multicenter Study of 2-year Outcomes Following Hyperthermia Therapy with Mitomycin C in Treating Non-Muscle Invasive Bladder Cancer: HIVEC-E.", "datePublished": "2022-12-14", "url": "https://questionsmedicales.fr/article/38994184", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3233/BLC-220026" } }, { "@type": "ScholarlyArticle", "name": "Assessment of predictors of early postoperative complications after primary robotically assisted Roux-en-Y gastric bypass: a multicenter, retrospective cohort study.", "datePublished": "2022-12-09", "url": "https://questionsmedicales.fr/article/36484858", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s00464-022-09766-x" } }, { "@type": "ScholarlyArticle", "name": "Prescription Opioid Use among Patients with Chronic Noncancer Pain before and after the COVID-19 Outbreak in Taiwan: A Multicenter Prospective Observational Study.", "datePublished": "2022-12-06", "url": "https://questionsmedicales.fr/article/36553984", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3390/healthcare10122460" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Organisations et économie des soins de santé", "item": "https://questionsmedicales.fr/mesh/D004472" }, { "@type": "ListItem", "position": 3, "name": "Organismes", "item": "https://questionsmedicales.fr/mesh/D009938" }, { "@type": "ListItem", "position": 4, "name": "Agences gouvernementales", "item": "https://questionsmedicales.fr/mesh/D006077" }, { "@type": "ListItem", "position": 5, "name": "Gouvernement fédéral", "item": "https://questionsmedicales.fr/mesh/D035082" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Gouvernement fédéral - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Gouvernement fédéral", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-08", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Gouvernement fédéral", "description": "Comment le gouvernement fédéral évalue-t-il les épidémies ?\nQuelles sont les méthodes de surveillance des maladies ?\nQuel rôle joue le gouvernement dans le diagnostic des maladies ?\nComment le gouvernement fédéral soutient-il le diagnostic précoce ?\nQuelles sont les normes de diagnostic établies par le gouvernement ?", "url": "https://questionsmedicales.fr/mesh/D035082?mesh_terms=Multicenter+Studies+as+Topic&page=1000#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Gouvernement fédéral", "description": "Comment le gouvernement informe-t-il sur les symptômes des maladies ?\nQuels symptômes sont souvent associés aux épidémies ?\nComment le gouvernement traite-t-il les symptômes des maladies chroniques ?\nQuelles ressources le gouvernement offre pour les symptômes mentaux ?\nComment le gouvernement évalue-t-il les symptômes des nouvelles maladies ?", "url": "https://questionsmedicales.fr/mesh/D035082?mesh_terms=Multicenter+Studies+as+Topic&page=1000#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Gouvernement fédéral", "description": "Quelles campagnes de prévention le gouvernement mène-t-il ?\nComment le gouvernement soutient-il la prévention des maladies chroniques ?\nQuelles sont les recommandations gouvernementales pour la prévention ?\nComment le gouvernement évalue-t-il l'efficacité des programmes de prévention ?\nQuelles ressources le gouvernement offre pour la prévention des maladies ?", "url": "https://questionsmedicales.fr/mesh/D035082?mesh_terms=Multicenter+Studies+as+Topic&page=1000#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Gouvernement fédéral", "description": "Quel est le rôle du gouvernement dans le financement des traitements ?\nComment le gouvernement régule-t-il les traitements médicaux ?\nQuelles sont les initiatives gouvernementales pour les traitements innovants ?\nComment le gouvernement assure-t-il l'accès aux traitements ?\nQuelles sont les politiques de traitement des maladies infectieuses ?", "url": "https://questionsmedicales.fr/mesh/D035082?mesh_terms=Multicenter+Studies+as+Topic&page=1000#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Gouvernement fédéral", "description": "Comment le gouvernement gère-t-il les complications des maladies ?\nQuelles sont les complications courantes des maladies infectieuses ?\nComment le gouvernement informe-t-il sur les complications possibles ?\nQuelles sont les politiques pour gérer les complications des maladies chroniques ?\nComment le gouvernement évalue-t-il les complications des traitements ?", "url": "https://questionsmedicales.fr/mesh/D035082?mesh_terms=Multicenter+Studies+as+Topic&page=1000#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Gouvernement fédéral", "description": "Quels facteurs de risque le gouvernement identifie-t-il ?\nComment le gouvernement aborde-t-il les facteurs de risque ?\nQuelles données le gouvernement utilise pour évaluer les facteurs de risque ?\nComment le gouvernement sensibilise-t-il aux facteurs de risque ?\nQuelles initiatives le gouvernement prend-il pour réduire les facteurs de risque ?", "url": "https://questionsmedicales.fr/mesh/D035082?mesh_terms=Multicenter+Studies+as+Topic&page=1000#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment le gouvernement fédéral évalue-t-il les épidémies ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Il utilise des données épidémiologiques et des rapports de santé publique pour évaluer les épidémies." } }, { "@type": "Question", "name": "Quelles sont les méthodes de surveillance des maladies ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les méthodes incluent les enquêtes, les systèmes de notification et les analyses de données." } }, { "@type": "Question", "name": "Quel rôle joue le gouvernement dans le diagnostic des maladies ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Il établit des protocoles de diagnostic et finance des recherches pour améliorer les méthodes." } }, { "@type": "Question", "name": "Comment le gouvernement fédéral soutient-il le diagnostic précoce ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Il finance des programmes de dépistage et sensibilise le public aux signes précoces." } }, { "@type": "Question", "name": "Quelles sont les normes de diagnostic établies par le gouvernement ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Le gouvernement établit des lignes directrices basées sur des preuves pour le diagnostic." } }, { "@type": "Question", "name": "Comment le gouvernement informe-t-il sur les symptômes des maladies ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Il publie des brochures, des sites web et des campagnes de sensibilisation sur les symptômes." } }, { "@type": "Question", "name": "Quels symptômes sont souvent associés aux épidémies ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes varient, mais incluent souvent fièvre, toux, et fatigue selon la maladie." } }, { "@type": "Question", "name": "Comment le gouvernement traite-t-il les symptômes des maladies chroniques ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Il finance des programmes de gestion des maladies chroniques et des traitements symptomatiques." } }, { "@type": "Question", "name": "Quelles ressources le gouvernement offre pour les symptômes mentaux ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Il propose des lignes d'assistance, des programmes de santé mentale et des ressources en ligne." } }, { "@type": "Question", "name": "Comment le gouvernement évalue-t-il les symptômes des nouvelles maladies ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Il collabore avec des experts pour identifier et évaluer les symptômes émergents." } }, { "@type": "Question", "name": "Quelles campagnes de prévention le gouvernement mène-t-il ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Il organise des campagnes de vaccination, de dépistage et de sensibilisation à la santé." } }, { "@type": "Question", "name": "Comment le gouvernement soutient-il la prévention des maladies chroniques ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Il finance des programmes de promotion de la santé et d'éducation sur les modes de vie sains." } }, { "@type": "Question", "name": "Quelles sont les recommandations gouvernementales pour la prévention ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Le gouvernement publie des lignes directrices sur l'alimentation, l'exercice et le dépistage." } }, { "@type": "Question", "name": "Comment le gouvernement évalue-t-il l'efficacité des programmes de prévention ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Il utilise des études d'impact et des analyses de données pour évaluer les programmes." } }, { "@type": "Question", "name": "Quelles ressources le gouvernement offre pour la prévention des maladies ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Il propose des ressources en ligne, des brochures et des ateliers communautaires." } }, { "@type": "Question", "name": "Quel est le rôle du gouvernement dans le financement des traitements ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Il finance la recherche et l'accès aux traitements par le biais de subventions et de programmes." } }, { "@type": "Question", "name": "Comment le gouvernement régule-t-il les traitements médicaux ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Il établit des agences pour approuver et surveiller les traitements avant leur mise sur le marché." } }, { "@type": "Question", "name": "Quelles sont les initiatives gouvernementales pour les traitements innovants ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Le gouvernement soutient des programmes de recherche et des essais cliniques pour les innovations." } }, { "@type": "Question", "name": "Comment le gouvernement assure-t-il l'accès aux traitements ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Il met en place des programmes d'assurance santé et des politiques d'accès aux soins." } }, { "@type": "Question", "name": "Quelles sont les politiques de traitement des maladies infectieuses ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Le gouvernement élabore des protocoles de traitement basés sur des recommandations scientifiques." } }, { "@type": "Question", "name": "Comment le gouvernement gère-t-il les complications des maladies ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Il met en place des protocoles de traitement et des programmes de suivi pour les complications." } }, { "@type": "Question", "name": "Quelles sont les complications courantes des maladies infectieuses ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Les complications peuvent inclure des infections secondaires, des séquelles et des hospitalisations." } }, { "@type": "Question", "name": "Comment le gouvernement informe-t-il sur les complications possibles ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Il publie des informations sur les risques et les complications associés aux maladies." } }, { "@type": "Question", "name": "Quelles sont les politiques pour gérer les complications des maladies chroniques ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Le gouvernement finance des programmes de gestion des complications et de réhabilitation." } }, { "@type": "Question", "name": "Comment le gouvernement évalue-t-il les complications des traitements ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Il surveille les effets secondaires et les complications par le biais de systèmes de rapport." } }, { "@type": "Question", "name": "Quels facteurs de risque le gouvernement identifie-t-il ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Il identifie des facteurs comme le tabagisme, l'obésité et le manque d'exercice dans ses études." } }, { "@type": "Question", "name": "Comment le gouvernement aborde-t-il les facteurs de risque ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Il met en place des politiques de santé publique pour réduire les facteurs de risque identifiés." } }, { "@type": "Question", "name": "Quelles données le gouvernement utilise pour évaluer les facteurs de risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Il utilise des enquêtes de santé, des études épidémiologiques et des données démographiques." } }, { "@type": "Question", "name": "Comment le gouvernement sensibilise-t-il aux facteurs de risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Il organise des campagnes d'éducation et de sensibilisation sur les comportements à risque." } }, { "@type": "Question", "name": "Quelles initiatives le gouvernement prend-il pour réduire les facteurs de risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Il finance des programmes de prévention et des interventions communautaires ciblées." } } ] } ] }

Sources (10000 au total)

Estimation of the physiologic ability and surgical stress scoring system as a useful predictor of postoperative recurrence in patients with stage II colorectal cancer: a multicenter study.

We determined the usefulness of the estimation of physiologic ability and surgical stress (E-PASS), initially reported as a predictive factor for postoperative morbidity and mortality, as a prognostic... Overall, 739 patients who underwent proctocolectomy for CRC at Tottori University Hospital and affiliated hospitals and histologically diagnosed with stage II CRC were included in the current study.... A receiver operating characteristic (ROC) analysis of the five-year recurrence-free survival indicated that the comprehensive risk score (CRS) of E-PASS predicted postoperative recurrence. A multivari... The CRS predicts postoperative recurrence in patients with stage II CRC....

The 31-gene expression profile test informs sentinel lymph node biopsy decisions in patients with cutaneous melanoma: results of a prospective, multicenter study.

The 31-gene expression profile test (Class 1A: low-risk; 1B/2A: intermediate-risk; 2B: high-risk) is validated to identify patients with cutaneous melanoma who can safely forego sentinel lymph node bi... Patients with T1-T2 tumors eligible for SLNB were seen by surgical oncologists (89.1%), dermatologists (7.8%), and medical oncologists (3.1%). After receiving 31-GEP results but before SLNB, clinician... One hundred clinical decisions (52.4%) were influenced by the 31-GEP to forego SLNB and 70% (70/100) were not performed. Of the 30 performed, 0% (0/30) were positive. The 31-GEP influenced sixty-three... In this prospective, multicenter study, clinicians demonstrated clinically meaningful use of the 31-GEP test to forego or pursue SLNB in patients with T1-T2 tumors resulting in a significant, risk app...

A Multicenter Study of 2-year Outcomes Following Hyperthermia Therapy with Mitomycin C in Treating Non-Muscle Invasive Bladder Cancer: HIVEC-E.

High grade, non-muscle invasive bladder cancer (NMIBC) is usually treated with intravesical Bacillus Calmette-Guérin. Chemohyperthermia therapy (CHT) may be a novel alternative therapy for the treatme... To evaluate the recurrence-free survival (RFS) of patients treated with CHT using the Combat bladder recirculation system (BRS) for NMIBC.... This was a prospective multi-institutional study of 1,028 consecutive patients with NMIBC undergoing CHT between 2012 and 2020. A total of 835 patients were treated with CHT with Mitomycin C (MMC). Di... Median follow up was 22.4 months (Interquartile range (IQR): 12.8 -35.8). Median age was 70.4 years (IQR: 62.1 -78.6). A total of 557 (66.7%), 172 (20.6) and 74 (8.9%) of patients were classified to B... CHT with MMC using the Combat BRS is effective in the medium term and has a favorable adverse event profile....

Assessment of predictors of early postoperative complications after primary robotically assisted Roux-en-Y gastric bypass: a multicenter, retrospective cohort study.

Robotic Roux-en-Y gastric bypass (RRYGB) is performed in an increasing number of bariatric centers worldwide. Previous studies have identified a number of demographic and clinical variables as predict... A retrospective analysis of two prospective databases containing patients who underwent RRYGB between 2006 and 2019 at two high volumes, accredited bariatric centers was performed. Primary outcome was... Data of 1276 patients were analyzed, including 958 female and 318 male patients. Rates of overall and severe 30 day complications were 12.5% (160/1276) and 3.9% (50/1276), respectively. Rate of 30 day... This study identified male sex and ASA score >2 as independent predictors of early postoperative complications after RRYGB. These data suggest a potentially different risk profile in terms of early po...

Prescription Opioid Use among Patients with Chronic Noncancer Pain before and after the COVID-19 Outbreak in Taiwan: A Multicenter Prospective Observational Study.

The COVID-19 outbreak disrupted medical access for patients receiving chronic opioid therapy. This study investigated their prescription opioid dosages before and after the 2020 outbreak in Taiwan.... A prospective questionnaire survey was conducted among registered outpatients receiving long-term opioids before July 2019 in Taiwan. The questionnaire included items from the Taiwanese Brief Pain Inv... After a mean of 531 days, the questionnaire responses of 103 of the initial 117 respondents were reviewed. Daily opioid doses decreased for 31 respondents (30.1%), remained roughly equivalent (defined... The COVID-19 outbreak in 2020 did not interrupt access to long-term opioid prescriptions for most registered patients with chronic pain in Taiwan. Less fentanyl patch use was observed in participants ...

Efficacy of extended focused assessment with sonography for trauma using a portable handheld device for detecting hemothorax in a low resource setting; a multicenter longitudinal study.

Chest trauma is one of the most important and commonest injuries that require timely diagnosis, accounting for 25-50% of trauma related deaths globally. Although CT scan is the gold standard for detec... This was an observational longitudinal study that enrolled 104 study participants with chest trauma. Informed consent was obtained from all participants. A questionnaire was administered and eFAST, ch... eFAST was found to be superior to chest X-ray with sensitivity of 96.1% versus 45.1% respectively. The accuracy was also higher for eFAST (96.4% versus 49.1%) but the specificity was the same at 100.0... This study revealed that eFAST was more sensitive at detecting haemothorax among chest trauma patients compared to chest X-ray. All patients presenting with chest trauma should have bedside eFAST for ...

Incidence and predictors of tuberculosis among children on antiretroviral therapy at northeast Ethiopia comprehensive specialized hospitals, 2022; A multicenter retrospective follow-up study.

Around the world, tuberculosis (TB) is the most common cause of mortality and morbidity in both adults and children. The incidence of tuberculosis (TB) is increased worldwide by co-infection with the ... An institution-based retrospective follow-up study was carried out in northeast Ethiopia's Comprehensive Specialized Hospitals, among 362 children on antiretroviral therapy from January 1, 2007, to Se... Among the 358 Human Immunodeficiency Virus-infected children, two-thirds (69.3%) were over ten years old. The overall tuberculosis incidence rate was 2.0 (95%CI: 1.5-2.6) per 100 person-years with a t... The incidence of tuberculosis in children infected with HIV/AIDS was high in this study. The risk of tuberculosis (TB) in HIV/AIDS-infected children has been linked to WHO stages III and IV, severe st...

Comparative Analysis of Commercially Available Typhoid Point-of-Care Tests: Results of a Prospective and Hybrid Retrospective Multicenter Diagnostic Accuracy Study in Kenya and Pakistan.

Blood and bone marrow cultures are considered the gold standard for the diagnosis of typhoid, but these methods require infrastructure and skilled staff that are not always available in low- and middl...

Clinicopathological Features of Breast Cancer in Relation to Exposure of Cycling Reproductive Hormones: A Multicenter Retrospective Study of 14,731 Patients Diagnosed with Invasive Breast Cancer.

BACKGROUND Reproductive period for women, begins at menarche and ends at menopause, which represented the total time period of exposure to cycling reproductive hormones. The potential associations bet...

Proximal hyperdense middle cerebral artery sign is associated with increased risk of asymptomatic hemorrhagic transformation after endovascular thrombectomy: a multicenter retrospective study.

To investigate whether hyperdense middle cerebral artery sign (HMCAS) on pretreatment no-contrast CT (NCCT) is associated with hemorrhagic transformation (HT) after endovascular thrombectomy (EVT).... Patients with acute middle cerebral artery (MCA) occlusion who received EVT in three comprehensive hospitals were retrospectively evaluated. They were divided into four groups based on the presence or... 318 patients were included, among whom 149 (46.9%) had HMCAS. Patients in the proximal positive HMCAS group had higher National Institute of Health Stroke Scale scores and lower Alberta Stroke Program... Proximal HMCAS on initial NCCT was independently associated with aHT in patients who received EVT for acute MCA occlusion. Both aHT and sHT had a detrimental effect on clinical outcome....